06/11/2021: Lab Alert: Stop Using Innova SARS-CoV-2 Antigen Rapid Qualitative Test

CDC's Laboratory Outreach Communication System (LOCS)

Audience: Individuals Performing COVID-19 Testing

Level: Laboratory Alert

The U.S. Food and Drug Administration (FDA) issued a safety communicationexternal icon warning test users and caregivers, health care providers, and testing program organizers to stop using the Innova SARS-CoV-2 Antigen Rapid Qualitative Test for diagnostic use. FDA has significant concerns that the performance of the test has not been adequately established, and its use could present a health risk. Additionally, FDA has not authorized, cleared, or approved the test for commercial distribution or use in the United States, as required by law. The FDA has classified the recall of this test as a Class I recallexternal icon, the most serious type of recall.

The Innova SARS-CoV-2 Antigen Rapid Qualitative Test is also distributed under the following names:

  • Innova COVID-19 Self-Test Kit (3T Configuration)
  • Innova SARS-CoV-2-Antigen Rapid Qualitative Test (7T Configuration)
  • Innova SARS-CoV-2-Antigen Rapid Qualitative Test (25T Configuration)

For listings of FDA-authorized tests, see:

 

We encourage you to review the safety communication in detail and share this message widely with your networks.

Opt in to receive emails from the CDC Laboratory Outreach Communication System (LOCS)external icon.

Online Resources:

 

If you have any questions, please contact us at LOCS@cdc.gov.

Thank you,

Laboratory Outreach Communication System | Division of Laboratory Systems (DLS)

Center for Surveillance, Epidemiology, and Laboratory Services (CSELS)

Centers for Disease Control and Prevention (CDC)

LOCS@cdc.gov

www.cdc.gov/csels/dls/locs

Page last reviewed: April 12, 2021